IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Inhibikase Therapeutics, Inc. Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.	United States of America	IKT
Inhibrx Biosciences, Inc. Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.	United States of America	INBX
InMed Pharmaceuticals Inc. Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.	United States of America	INM
Inmune Bio, Inc. Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.	United States of America	INMB
Innate Pharma SA Developing first-in-class antibody immunotherapies for cancer via the innate immune system.	United States of America	IPHA
INOVIO PHARMACEUTICALS, INC. Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.	United States of America	INO
Insight Molecular Diagnostics Inc. Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.	United States of America	IMDX
INSMED Inc Develops and commercializes innovative therapies for serious and rare diseases.	United States of America	INSM
Instil Bio, Inc. Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.	United States of America	TIL
Intellia Therapeutics, Inc. Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.	United States of America	NTLA